Analytical Data
-
Gene name
ARHGAP17
- Application
-
Alternative Names
RICH1; NADRIN; WBP15; RhoGAP interacting with CIP4 homologs protein 1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q3UIA2
-
Expression Region
Gln14~Phe442
-
Molecular Weight
52kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARHGAP17 (Rho GTPase-activating protein 17) is a member of the RhoGAP family, playing a significant role in regulating the Rho family of GTPases, which are key players in various cellular processes, including cell migration, proliferation, and morphology. Dysregulation of RhoGTPases has been implicated in a range of pathological conditions, including cancer and neurological disorders. The interest in ARHGAP17 stems from its potential involvement in these diseases, as its expression levels and activity could influence tumor progression and cell signaling pathways. Recent studies have suggested that ARHGAP17 might modulate cell adhesion and cytoskeletal dynamics, further linking it to cancer metastasis. Given these critical functions, researchers are focusing on the recombinant expression and characterization of ARHGAP17 to elucidate its mechanistic role in cellular functions and its potential as a therapeutic target. Understanding ARHGAP17's interaction with Rho GTPases and other molecular partners through structural and functional analyses can provide insights into its contribution to disease processes and may help in the development of novel interventions aimed at manipulating its activity for therapeutic benefit.
